Reading SPRB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SPRB free→Reading SPRB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SPRB free→QuarterlyIQ Insights · SPRB
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(1.6) + peer(0.2*0.0) + term(0.0) → 0.58% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and has been missing across recent quarters. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On May 13, 2026, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026 and providing corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company also reported cash and cash equivalents of $107.3 million as of April 30, 2026. This estimate is preliminary…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On March 9, 2026, the Company issued a press release announcing its financial results for the full year ended December 31, 2025 and providing corporate updates (the “Press Release”). The full text of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this
Results of Operations and Financial Condition. On January 8, 2026, the Company announced that its preliminary unaudited cash and cash equivalents as of December 31, 2025 were approximately $48.9 million. The Company has not yet completed its quarter-end and year-end financial close process for the quarter and year ended December 31, 2025. This estimate of the Company’s cash and cash equivalents as of December 31, 2025 is preliminary, has not been audited and is subject to change upon completi…
Results of Operations and Financial Condition. On November 10, 2025, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2025 and providing corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this
Results of Operations and Financial Condition. On August 14, 2025, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2025 and providing corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this
Results of Operations and Financial Condition. On May 6, 2025, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2025 and providing corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this
Results of Operations and Financial Condition. On April 15, 2025, Spruce Biosciences, Inc. (the “Company”) issued a press release providing a corporate update that included updates on its new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B, anticipated upcoming milestones, and its cash and cash equivalents balance of $38.8 million as of December 31, 2024 (the “Press Release”). The full text of the Press Releas…